FY2025 Earnings Estimate for Amgen Issued By William Blair

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities research analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report issued on Wednesday, February 5th. William Blair analyst M. Phipps now forecasts that the medical research company will earn $20.55 per share for the year, down from their prior estimate of $21.34. William Blair has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $19.56 per share. William Blair also issued estimates for Amgen's Q1 2025 earnings at $3.89 EPS, Q2 2025 earnings at $5.54 EPS, Q3 2025 earnings at $5.66 EPS, Q4 2025 earnings at $5.48 EPS, FY2026 earnings at $19.43 EPS and FY2027 earnings at $20.18 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%.

Several other brokerages also recently commented on AMGN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. UBS Group cut their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating on the stock in a report on Thursday, October 31st. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler Companies restated an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Finally, Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $314.83.

Amgen Trading Down 1.4 %

Shares of NASDAQ AMGN traded down $4.24 during midday trading on Friday, reaching $293.54. 3,388,255 shares of the stock were exchanged, compared to its average volume of 3,317,161. Amgen has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market capitalization of $157.79 billion, a price-to-earnings ratio of 37.59, a P/E/G ratio of 2.87 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50-day simple moving average of $272.04 and a two-hundred day simple moving average of $303.51.

Institutional Investors Weigh In On Amgen

Several hedge funds have recently bought and sold shares of AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter worth about $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter worth approximately $29,000. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $25,000. Matrix Trust Co bought a new stake in shares of Amgen in the third quarter valued at approximately $36,000. Finally, Synergy Investment Management LLC acquired a new stake in Amgen during the fourth quarter worth approximately $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.69% of the company's stock.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.24%. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.